#Denmark #Biomarkers #Nordic Bioscience #Herlev #nordicEndotrophin™

Nordic Bioscience Unveils NordicEndotrophin™

On May 16, 2025, Nordic Bioscience, based in Herlev, Denmark, announced the launch of its latest innovation, nordicEndotrophin™. This fully automated, high-precision assay is designed to selectively quantify the intact signaling hormone endotrophin, consisting of 77 amino acids. The assay has received certification from Nordic Bioscience’s CAP/CLIA accredited laboratory, making it a significant addition to the company's existing biomarker product line.

A New Era in Biomarker Testing

This cutting-edge assay not only demonstrates prognostic utility in fibrosis and cancer studies but also complements products such as nordicPRO-C6™ and nordicPRO-C3™, which are focused on evaluating the fibro-inflammatory axis in chronic diseases. The ability to provide a comprehensive solution for assessing the risk of chronic illnesses is groundbreaking. With recent implementation of the PRO-C3 assay on Roche's in vitro diagnostic platforms, nordicEndotrophin™ enhances risk stratification and pharmacodynamic monitoring.

The discovery of endotrophin dates back to 2012, when it was identified as a hormone derived from collagen type VI. This specific type of collagen is involved in the activation of fibroblasts, which subsequently contributes to fibrosis in various organs. In fact, inflammatory processes associated with fibrosis account for approximately 40% of deaths in Western countries, with obesity further exacerbating fibroblast activation in the liver, kidneys, and heart.

Research indicates that patients with double the circulating levels of endotrophin face a 100% increase in mortality risk. Thus, accurately quantifying endotrophin allows researchers to draw connections between wound healing, fibrotic progression, and patient outcomes—an integral aspect of precision medicine approaches targeting this dangerous hormone.

Complementary Products and Applications

While PRO-C6 measures the overall formation of collagen type VI through a portable ELISA platform, nordicEndotrophin™ focuses specifically on the intact endotrophin hormone. This targeted approach allows for enhanced risk stratification and prognostic value that complements the fibrotic-based pharmacodynamic information provided by PRO-C6.

Dr. Morten Karsdal, CEO of Nordic Bioscience, stated, “Endotrophin is a significant emerging prognostic biomarker. In a study involving patients with HFpEF, endotrophin, together with PRO-C6, outperformed NT-proBNP regarding mortality and hospitalization risk.” The integration of these biomarkers will refine patient stratification and treatment monitoring for individuals with obesity, fibrotic diseases, and autoimmune endotypes.

Advanced Automated Solutions

The compact sandwich assay of nordicEndotrophin™, which is now available at Nordic Bioscience's CAP/CLIA accredited laboratory, utilizes fully automated platforms that ensure high precision and performance. Researchers are encouraged to consider using nordicEndotrophin™ alongside the nordicPRO-C3™ and nordicPRO-C6™ assays for accelerated profiling of the fibro-inflammatory characteristics of drugs. Together, these assays facilitate precise risk stratification, dose selection, patient enrichment, mechanism validation, and treatment monitoring in antifibrotic and oncological clinical trials.

About Nordic Bioscience

Nordic Bioscience, a leading Danish biomarker company located in Herlev, is committed to developing biomarkers using proprietary neoepitope technology. The company's expertise in biomarker development is synergistically combined with preclinical and clinical research efforts, enabling efficient and objective decision-making for compound selection and development in clinical trials while providing value to patients in the diagnostic space.

For more information about Nordic Bioscience and its innovative solutions, please visit Nordic Bioscience Official Website.